(Q33396066)

English

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase III clinical trial

0 references

follicular lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Pier Luigi Zinzani

19

object named as

Pier Luigi Zinzani

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Evgenii A Osmanov

object named as

Evgenii A Osmanov

2

0 references

object named as

Jan Walewski

9

0 references

12

object named as

Ofer Shpilberg

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Bertrand Coiffier

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xiaonan Hong

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adriana Scheliga

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jiri Mayer

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Fritz Offner

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Simon Rule

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Adriana Teixeira

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sven de Vos

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael Crump

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dixie-Lee Esseltine

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eugene Zhu

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Christopher Enny

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Panteli Theocharous

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Helgi van de Velde

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Yusri A Elsayed

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

LYM-3001 study investigators

20

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

1 July 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

773-784

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M.D. Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma: time for a re-think?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Reassessing the Standard of Care in Indolent Lymphoma: A Clinical Update to Improve Clinical Practice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Targeted treatment and new agents in follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanistic rationale and clinical evidence for the efficacy of proteasome inhibitors against indolent and mantle cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Additive cytotoxic effect of bortezomib in combination with anti-CD20 or anti-CD52 monoclonal antibodies on chronic lymphocytic leukemia cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized phase II study of weekly or twice-weekly bortezomib plus rituximab in patients with relapsed or refractory follicular or marginal-zone B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Follicular lymphoma international prognostic index.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase 2 study of weekly bortezomib in mantle cell and follicular lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970150-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(11)70150-4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33396066&oldid=1993586321"